Abstract:A facile hydrothermal strategy is employed to construct a core‐shell heterostructure sonosensitizer comprising metalloporphyrin (Fe‐TCPP) metal organic frameworks (MOFs) and bright DSNPs (NaErF4:Yb@NaLuF4). The coordination of Fe3+ into the macrocycle of TCPP at the MOFs shell is confirmed resulting in a marked decrease in TCPP phosphorescence and a significant increase in singlet oxygen generation, and the subsequent reduction of Fe3+ by GSH facilitates the restoration of DSNPs at 1525 nm, thereby significantly augmenting the generation of reactive oxygen species and enabling real‐time monitoring of sonodynamic therapy. Noninvasive sonodynamic therapy (SDT) shows promise for brain glioma treatment due to deep tissue‐penetrating capabilities (>10 cm) of ultrasound and high spatial resolutions. Yet, this technique is hindered by inefficient production of reactive oxygen species (ROS), resulting from the hypoxic tumor microenvironment (TME), high level of ROS scavenger glutathione (GSH), and the inability to visualize glioma in vivo for precise treatment management and monitoring in current sonosentizers. To address these challenges, we fabricated a core‐shell heterostructure sonosensitizer (labeled as DFM), in which meso‐tetra (4‐carboxyphenyl) porphine (TCPP) porphyrin metal‐organic frameworks (MOF, PCN‐224(Fe)) serve as a porous shell to contain approved chemotherapeutics sorafenib (SRF) to effectively inhibit GSH synthesis, while NaErF4:Yb@NaLuF4 nanoparticles as the core provide TME‐responsive NIR IIb (≈1500–1800 nm) luminescence at 1525 for precise optical imaging. Coordination of Fe3+ into the macrocycle of TCPP at the MOFs shell is found to, besides triggering ferroptosis, reduce TCPP phosphorescence (23% decrease) and increase the triplet state (T1) oxygen quenching, substantially promoting the singlet oxygen generation (2.6‐fold increase). Furthermore, GSH in TME facilitates the reduction of Fe3+ to Fe2+, thereby eliminating the luminescence quenching of Fe3+ and augmenting the NIR IIb luminescence of Er3+ (5‐fold increase) for nanoagents accumulation imaging in intracranial glioma, realizing dynamical monitoring of SDT processes. Compared to control groups, in vitro and in vivo experiments confirm the effective ROS generation and results in a 6‐fold volume reduction of brain gliomas, reaching a survival rate of 80% at 30 days posttreatment.

Amorphous 2D Mn-doped CoMo-layered double hydroxide nanosheets for magnetic resonance imaging-guided sonodynamic cancer therapy

Bifunctional Bismuth-Based Layered Double Hydroxide Sonosensitizer for Magnetic Resonance Imaging-Guided Sonodynamic Cancer Therapy

Boosting the sonodynamic performance of CoBiMn-layered double hydroxide nanoparticles via tumor microenvironment regulation for ultrasound imaging-guided sonodynamic therapy

Mn(II) Optimized Sono/Chemodynamic Effect of Porphyrin‐Metal–Organic Framework Nanosheets for MRI‐Guided Colon Cancer Therapy and Metastasis Suppression

MnO2 coated multi-layer nanoplatform for enhanced sonodynamic therapy and MR imaging of breast cancer

Two-dimensional semiconductor heterojunction nanostructure for mutually synergistic sonodynamic and chemoreactive cancer nanotherapy

A Core-Shell Nanoplatform for Synergistic Enhanced Sonodynamic Therapy of Hypoxic Tumor via Cascaded Strategy

Vacancy-engineered Mn-doped iron oxide nano-crystals for enhanced sonodynamic therapy through self-supplied oxygen

Two‐dimensional Ultrathin Iron Doped Bismuth Oxychloride Nanosheets with Rich Oxygen Vacancies for Enhanced Sonodynamic Therapy

Biodegradable Fe-Doped Vanadium Disulfide Theranostic Nanosheets for Enhanced Sonodynamic/Chemodynamic Therapy

Boosting the Sonodynamic Cancer Therapy Performance of 2D Layered Double Hydroxide Nanosheet‐Based Sonosensitizers Via Crystalline‐to‐Amorphous Phase Transformation

Single Atom Iron‐Doped Graphic‐Phase C3N4 Semiconductor Nanosheets for Augmented Sonodynamic Melanoma Therapy Synergy with Endowed Chemodynamic Effect

Nano-Sonosensitized Sonodynamic Nanomedicine Augments Tumor-Selective Catalytic Tumor Eradication

Dual-modality magnetic resonance/optical imaging-guided sonodynamic therapy of pancreatic cancer with metal—organic nanosonosensitizer

Engineering layered double hydroxide-based sonocatalysts for enhanced sonodynamic-immunotherapy

Ultrasmall Iron-Doped Titanium Oxide Nanodots for Enhanced Sonodynamic and Chemodynamic Cancer Therapy

Integrated organosilica nanomedicine enables sonoimaging, sonochemistry and antitumor sonodynamic therapy

Catalase-like pleated niobium carbide MXene loaded with polythiophene for oxygenated sonodynamic therapy in solid tumor

Novel 131-iodine labeled and ultrasound-responsive nitric oxide and reactive oxygen species controlled released nanoplatform for synergistic sonodynamic/nitric oxide/chemodynamic/radionuclide therapy

Metal–Organic Framework (MOF)‐Based Ultrasound‐Responsive Dual‐Sonosensitizer Nanoplatform for Hypoxic Cancer Therapy

Metalloporphyrin MOFs‐Based Nanoagent Enabling Tumor Microenvironment Responsive Sonodynamic Therapy of Intracranial Glioma Signaled by NIR‐IIb Luminescence Imaging